Journal Article

Initiation of Highly Active Antiretroviral Therapy at CD4<sup>+</sup> T Lymphocyte Counts of >350 cells/mm<sup>3</sup>: Disease Progression, Treatment Durability, and Drug Toxicity

Timothy R. Sterling, Richard E. Chaisson and Richard D. Moore

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 36, issue 6, pages 812-815
Published in print March 2003 | ISSN: 1058-4838
Published online March 2003 | e-ISSN: 1537-6591 | DOI: https://dx.doi.org/10.1086/367934
Initiation of Highly Active Antiretroviral Therapy at CD4+ T Lymphocyte Counts of >350 cells/mm3: Disease Progression, Treatment Durability, and Drug Toxicity

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

We compared clinical disease progression in 159 human immunodeficiency virus (HIV)-infected persons for whom highly active antiretroviral therapy (HAART) was initiated when they had CD4+ T lymphocyte counts of 350–499 cells/mm3 with progression in 174 HIV-infected patients for whom it was not. Disease progression did not differ between the 2 groups (P =.21, log-rank test). Fifty-three percent of the 159 treated patients had HIV type 1 RNA levels of >400 copies/mL at the most recent evaluation, and 41% had experienced adverse drug reactions necessitating a change in regimen. These findings support the recommendation that HAART not be initiated for patients with CD4+ cell counts of >350 cells/mm3.

Journal Article.  2342 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.